These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32867830)

  • 1. Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: a protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA).
    Freites-Núñez D; Baillet A; Rodriguez-Rodriguez L; Nguyen MVC; Gonzalez I; Pablos JL; Balsa A; Vazquez M; Gaudin P; Fernandez-Gutierrez B
    Trials; 2020 Aug; 21(1):755. PubMed ID: 32867830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.
    van der Leeuw MS; Welsing PMJ; de Hair MJH; Jacobs JWG; Marijnissen ACA; Linn-Rasker SP; Fodili F; Bos R; Tekstra J; van Laar JM
    Trials; 2020 Apr; 21(1):313. PubMed ID: 32248829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial.
    Hartman L; Rasch LA; Klausch T; Bijlsma HWJ; Christensen R; Smulders YM; Ralston SH; Buttgereit F; Cutolo M; Da Silva JAP; Opris D; Rovenský J; Szamosi S; Middelink LM; Lems WF; Boers M
    Trials; 2018 Jan; 19(1):67. PubMed ID: 29370811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction Aided Tapering In rheumatoid arthritis patients treated with biOlogicals (PATIO): protocol for a randomized controlled trial.
    Messelink MA; van der Leeuw MS; den Broeder AA; Tekstra J; van der Goes MC; Heijstek MW; Lafeber F; Welsing PMJ
    Trials; 2022 Jun; 23(1):494. PubMed ID: 35710576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
    Clark W; Jobanputra P; Barton P; Burls A
    Health Technol Assess; 2004 May; 8(18):iii-iv, ix-x, 1-105. PubMed ID: 15130461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
    Navarro Coy NC; Brown S; Bosworth A; Davies CT; Emery P; Everett CC; Fernandez C; Gray JC; Hartley S; Hulme C; Keenan AM; McCabe C; Redmond A; Reynolds C; Scott D; Sharples LD; Pavitt S; Buch MH
    BMC Musculoskelet Disord; 2014 Dec; 15():452. PubMed ID: 25539805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial.
    Wientjes MHM; Atiqi S; Wolbink GJ; Nurmohamed MT; Boers M; Rispens T; de Vries A; van Vollenhoven RF; van den Bemt BJF; den Broeder AA
    Trials; 2021 Jun; 22(1):406. PubMed ID: 34147123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of progressively reducing biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis in persistent remission: a study protocol for a non-inferiority randomized, controlled, single-blind trial.
    Lei S; Li Z; Zhang X; Zhou S
    Trials; 2022 Jul; 23(1):600. PubMed ID: 35897052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arthroscopic synovectomy versus intra-articular injection of corticosteroids for the management of refractory psoriatic or rheumatoid arthritis of the wrist: study protocol for a randomized controlled trial (ARCTIC trial).
    d'Ailly PN; Deugd C; Schep NWL; Kuijper TM; Kok MR; Willemze A; Coert JH; de Jong PHP; Lam-Tse WK; van der Helm-van Mil AHM; Tchetverikov I; Weel-Koenders AEAM; Bisoendial RJ
    Trials; 2023 Mar; 24(1):229. PubMed ID: 36966310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic impact of rheumatoid arthritis (RA) biotherapies in France.
    Maravic M
    Joint Bone Spine; 2010 Jul; 77(4):319-24. PubMed ID: 20493751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial.
    Porter D; van Melckebeke J; Dale J; Messow CM; McConnachie A; Walker A; Munro R; McLaren J; McRorie E; Packham J; Buckley CD; Harvie J; Taylor P; Choy E; Pitzalis C; McInnes IB
    Lancet; 2016 Jul; 388(10041):239-47. PubMed ID: 27197690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel optical spectral transmission (OST)-guided versus conventionally disease activity-guided treatment: study protocol of a randomized clinical trial on guidance of a treat-to-target strategy for early rheumatoid arthritis.
    Besselink NJ; Westgeest AAA; Klaasen R; Gamala M; van Woerkom JM; Tekstra J; Verhoeven MMA; Van Spil WE; Lafeber FPJG; Marijnissen ACA; Van Laar JM; Jacobs JWG
    Trials; 2019 Apr; 20(1):226. PubMed ID: 30999969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.
    Al-Laith M; Jasenecova M; Abraham S; Bosworth A; Bruce IN; Buckley CD; Ciurtin C; D'Agostino MA; Emery P; Gaston H; Isaacs JD; Filer A; Fisher BA; Huizinga TWJ; Ho P; Jacklin C; Lempp H; McInnes IB; Pratt AG; Östor A; Raza K; Taylor PC; van Schaardenburg D; Shivapatham D; Wright AJ; Vasconcelos JC; Kelly J; Murphy C; Prevost AT; Cope AP
    Trials; 2019 Jul; 20(1):429. PubMed ID: 31307535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessor, phase 4 study.
    Glinatsi D; Heiberg MS; Rudin A; Nordström D; Haavardsholm EA; Gudbjornsson B; Østergaard M; Uhlig T; Grondal G; Hørslev-Petersen K; van Vollenhoven R; Hetland ML
    Trials; 2017 Apr; 18(1):161. PubMed ID: 28376912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada.
    Weijers L; Baerwald C; Mennini FS; Rodríguez-Heredia JM; Bergman MJ; Choquette D; Herrmann KH; Attinà G; Nappi C; Merino SJ; Patel C; Mtibaa M; Foo J
    Rheumatol Int; 2017 Jul; 37(7):1111-1123. PubMed ID: 28560470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the therapeutic efficacy of the Chinese herbal medicine Yishen Tongbi decoction in patients with active rheumatoid arthritis: protocol for a randomized, controlled, noninferiority trial.
    Zhao L; Li M; Xu Y; Liu L; Zhang M; Chen G
    Trials; 2019 Dec; 20(1):801. PubMed ID: 31888728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.